Latest news with #CovalonTechnologiesLtd
Yahoo
27-05-2025
- Business
- Yahoo
Covalon Announces Exciting New Clinical Research Evaluating VALGuard® Vascular Access Line Guard
Study results have been selected for presentation at two prestigious scientific meetings and are advancing to publication MISSISSAUGA, Ontario, May 27, 2025--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced that exciting results from a clinical study evaluating the use of its VALGuard® Vascular Access Line Guard will be presented at two notable scientific meetings in the fall and are advancing through the publication process in a well-regarded academic journal. The study, conducted independent of Covalon, was a prospective pre- and post- intervention study of VALGuard® across critical and acute care units focused on the reduction of Central Line-Associated Blood Stream Infections (CLABSIs). "Blood streams infections are a serious, but largely preventable complication that tragically affect hundreds of thousands of patients each year, with a mortality rate estimated at 15% to 20%," said Dr. Kate Evely, Vice President of Clinical Affairs for Covalon. "Major hospitals all over the United States are adding VALGuard® as an important part of their infection prevention program's toolkit to protect intravenous lines from gross contamination, a known source of infection. The study results provide impactful real-world evidence on the use of VALGuard®. The forthcoming publication of this investigator-initiated study is a testament to the dedication of the research team and our shared goal of advancing patient care." As the authors advance the study through the final stages of the peer review process toward publication, they look forward to presenting their findings to their peers at two prestigious scientific conferences this fall – September's Association for Vascular Access Annual Scientific Meeting, the premier platform for the latest innovations and emerging technologies in vascular access, followed by October's American Nurses Credentialing Center (ANCC) Magnet Pathway Conference, which attracts more than 11,000 nursing leaders and professionals from around the world. About VALGuardVALGuard® is a unique innovative transparent line guard designed to protect IV line connections and hubs from external contaminants, including body fluids, and secretions that can lead to serious, life-threatening blood stream infections. Those interested in learning about Covalon's solutions may visit or follow Covalon on LinkedIn, Facebook, Instagram, or X. About CovalonCovalon is a leading medical device company dedicated to improving patient outcomes through innovative and compassionate medical products and technologies. Our expertise spans advanced wound care, vascular access, and surgical consumables, with a strong focus on enhancing healing, reducing healthcare-associated infections (HAIs), and protecting skin integrity. Our solutions are designed for patients and made for care providers. The Company is listed on the TSX Venture Exchange (COV) and trades on the OTCQX Market (CVALF). To learn more about Covalon, visit our website at Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan", "estimate", "expect", "intend", or variations of such words and phrases or state that certain actions, events, or results "may", "could", "would", "might", "will" or "will be taken", "occur", or "be achieved". In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts, but instead represent management's expectations, estimates, and projections regarding future events. Forward-looking statements involve risks and uncertainties, including, but not limited to, the factors described in greater detail in the "Risks and Uncertainties" section of our management's discussion and analysis of financial condition and results of operations for the year ended September 30, 2024, which is available on the Company's profile at any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company assumes no obligation to update or alter any forward-looking statements, whether as a result of new information, further events, or otherwise, except as required by law. View source version on Contacts To learn more about Covalon:Investor Relations, Covalon Technologies investors@ Website:
Business Wire
27-05-2025
- Health
- Business Wire
Covalon Announces Exciting New Clinical Research Evaluating VALGuard ® Vascular Access Line Guard
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced that exciting results from a clinical study evaluating the use of its VALGuard ® Vascular Access Line Guard will be presented at two notable scientific meetings in the fall and are advancing through the publication process in a well-regarded academic journal. The study, conducted independent of Covalon, was a prospective pre- and post- intervention study of VALGuard ® across critical and acute care units focused on the reduction of Central Line-Associated Blood Stream Infections (CLABSIs). 'Blood streams infections are a serious, but largely preventable complication that tragically affect hundreds of thousands of patients each year, with a mortality rate estimated at 15% to 20%,' said Dr. Kate Evely, Vice President of Clinical Affairs for Covalon. 'Major hospitals all over the United States are adding VALGuard ® as an important part of their infection prevention program's toolkit to protect intravenous lines from gross contamination, a known source of infection. The study results provide impactful real-world evidence on the use of VALGuard ®. The forthcoming publication of this investigator-initiated study is a testament to the dedication of the research team and our shared goal of advancing patient care.' As the authors advance the study through the final stages of the peer review process toward publication, they look forward to presenting their findings to their peers at two prestigious scientific conferences this fall – September's Association for Vascular Access Annual Scientific Meeting, the premier platform for the latest innovations and emerging technologies in vascular access, followed by October's American Nurses Credentialing Center (ANCC) Magnet Pathway Conference, which attracts more than 11,000 nursing leaders and professionals from around the world. About VALGuard VALGuard ® is a unique innovative transparent line guard designed to protect IV line connections and hubs from external contaminants, including body fluids, and secretions that can lead to serious, life-threatening blood stream infections. Those interested in learning about Covalon's solutions may visit or follow Covalon on LinkedIn, Facebook, Instagram, or X. About Covalon Covalon is a leading medical device company dedicated to improving patient outcomes through innovative and compassionate medical products and technologies. Our expertise spans advanced wound care, vascular access, and surgical consumables, with a strong focus on enhancing healing, reducing healthcare-associated infections (HAIs), and protecting skin integrity. Our solutions are designed for patients and made for care providers. The Company is listed on the TSX Venture Exchange (COV) and trades on the OTCQX Market (CVALF). To learn more about Covalon, visit our website at Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan", "estimate", "expect", "intend", or variations of such words and phrases or state that certain actions, events, or results 'may', 'could', 'would', 'might', 'will' or 'will be taken', 'occur', or 'be achieved'. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts, but instead represent management's expectations, estimates, and projections regarding future events. Forward-looking statements involve risks and uncertainties, including, but not limited to, the factors described in greater detail in the 'Risks and Uncertainties' section of our management's discussion and analysis of financial condition and results of operations for the year ended September 30, 2024, which is available on the Company's profile at any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company assumes no obligation to update or alter any forward-looking statements, whether as a result of new information, further events, or otherwise, except as required by law.
National Post
30-04-2025
- Business
- National Post
Covalon to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference on Tuesday, May 6, 2025
Article content MISSISSAUGA, Ontario — Covalon Technologies Ltd. (the 'Company' or 'Covalon') (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced that it will be presenting at the 2025 Bloom Burton & Co. Healthcare Investor Conference in Toronto on Tuesday, May 6, 2025 at 2:30 pm ET in Room 104 B at the Metro Toronto Convention Centre in Toronto. Brent Ashton, CEO of Covalon, will be hosting the presentation and answering questions at the conclusion. Article content Article content During his presentation, Mr. Ashton will share insights into the company's unwavering mission to prevent complications and save lives in healthcare through innovative, patient-centered technologies. He will also discuss Covalon's strong financial position and highlight the company's key growth drivers. Article content 'We are excited to be part of the Bloom Burton 2025 Healthcare Conference, one of the most respected events in the healthcare investment community,' said Ashton. 'Covalon's focus on delivering compassionate care solutions that reduce risks and improve patient outcomes has never been more important. Our strong balance sheet, combined with accelerating growth opportunities, positions us well to drive long-term value for patients, providers, and shareholders.' Article content The Bloom Burton Healthcare Investor Conference brings together healthcare companies and investors to connect and collaborate, offering a premier platform for sharing the latest industry developments and investment opportunities. Article content If you would like to book 1×1 investor meetings with Covalon, and to attend the Bloom Burton & Co. Healthcare Investor Conference, please make sure you are registered here: REGISTER Article content Covalon is a leading medical device company dedicated to improving patient outcomes through innovative and compassionate medical products and technologies. Our expertise spans advanced wound care, vascular access, and surgical consumables, with a strong focus on enhancing healing, reducing healthcare-associated infections (HAIs), and protecting skin integrity. Our solutions are designed for patients and made for care providers. The Company is listed on the TSX Venture Exchange (COV) and trades on the OTCQX Market (CVALF). To learn more about Covalon, visit our website at Article content The Bloom Burton & Co. Healthcare Investor Conference brings together U.S., Canadian and international investors who are interested in the latest developments in the Canadian healthcare sector. Attendees will have an opportunity to obtain corporate updates from the premier Canadian publicly traded and private companies through presentations and private meetings. Article content About Bloom Burton & Co. Article content Bloom Burton & Co. is a firm dedicated to accelerating returns in the healthcare sector for both investors and companies. Bloom Burton has an experienced team of medical, scientific, industry and capital markets professionals who perform a deep level of diligence, which combined with our creative and entrepreneurial approach, assists our clients in achieving the right monetization events. Bloom Burton and its affiliates provide capital raising, M&A advisory, equity research, strategic advisory, as well as company creation and incubation services. Bloom Burton Securities Inc. is a member of the Canadian Investment Regulatory Organization (CIRO) and is also a member of the Canadian Investor Protection Fund (CIPF). Article content Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Article content This news release may contain forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as 'seek', 'anticipate', 'plan', 'estimate', 'expect', 'intend', or variations of such words and phrases or state that certain actions, events, or results 'may', 'could', 'would', 'might', 'will' or 'will be taken', 'occur', or 'be achieved'. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts, but instead represent management's expectations, estimates, and projections regarding future events. Forward-looking statements involve risks and uncertainties, including, but not limited to, the factors described in greater detail in the 'Risks and Uncertainties' section of our management's discussion and analysis of financial condition and results of operations for the year ended September 30, 2024, which is available on the Company's profile at any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company assumes no obligation to update or alter any forward-looking statements, whether as a result of new information, further events, or otherwise, except as required by law. Article content Article content Article content Article content Contacts Article content Article content
Business Wire
30-04-2025
- Business
- Business Wire
Covalon to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference on Tuesday, May 6, 2025
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced that it will be presenting at the 2025 Bloom Burton & Co. Healthcare Investor Conference in Toronto on Tuesday, May 6, 2025 at 2:30 pm ET in Room 104 B at the Metro Toronto Convention Centre in Toronto. Brent Ashton, CEO of Covalon, will be hosting the presentation and answering questions at the conclusion. During his presentation, Mr. Ashton will share insights into the company's unwavering mission to prevent complications and save lives in healthcare through innovative, patient-centered technologies. He will also discuss Covalon's strong financial position and highlight the company's key growth drivers. 'We are excited to be part of the Bloom Burton 2025 Healthcare Conference, one of the most respected events in the healthcare investment community,' said Ashton. 'Covalon's focus on delivering compassionate care solutions that reduce risks and improve patient outcomes has never been more important. Our strong balance sheet, combined with accelerating growth opportunities, positions us well to drive long-term value for patients, providers, and shareholders.' The Bloom Burton Healthcare Investor Conference brings together healthcare companies and investors to connect and collaborate, offering a premier platform for sharing the latest industry developments and investment opportunities. If you would like to book 1x1 investor meetings with Covalon, and to attend the Bloom Burton & Co. Healthcare Investor Conference, please make sure you are registered here: REGISTER Conference Details Dates: Monday, May 5 – Tuesday, May 6, 2025 Time: 8:30 AM - 5:00 PM ET Location: Metro Toronto Convention Centre, North Building, 255 Front St W, Toronto, Ontario M5V 2W6 For those who are not able to attend the conference but are interested in learning more about Covalon's solutions, visit or follow Covalon on LinkedIn, Facebook, Instagram, or X. About Covalon Covalon is a leading medical device company dedicated to improving patient outcomes through innovative and compassionate medical products and technologies. Our expertise spans advanced wound care, vascular access, and surgical consumables, with a strong focus on enhancing healing, reducing healthcare-associated infections (HAIs), and protecting skin integrity. Our solutions are designed for patients and made for care providers. The Company is listed on the TSX Venture Exchange (COV) and trades on the OTCQX Market (CVALF). To learn more about Covalon, visit our website at About the Conference The Bloom Burton & Co. Healthcare Investor Conference brings together U.S., Canadian and international investors who are interested in the latest developments in the Canadian healthcare sector. Attendees will have an opportunity to obtain corporate updates from the premier Canadian publicly traded and private companies through presentations and private meetings. About Bloom Burton & Co. Bloom Burton & Co. is a firm dedicated to accelerating returns in the healthcare sector for both investors and companies. Bloom Burton has an experienced team of medical, scientific, industry and capital markets professionals who perform a deep level of diligence, which combined with our creative and entrepreneurial approach, assists our clients in achieving the right monetization events. Bloom Burton and its affiliates provide capital raising, M&A advisory, equity research, strategic advisory, as well as company creation and incubation services. Bloom Burton Securities Inc. is a member of the Canadian Investment Regulatory Organization (CIRO) and is also a member of the Canadian Investor Protection Fund (CIPF). Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan", "estimate", "expect", "intend", or variations of such words and phrases or state that certain actions, events, or results 'may', 'could', 'would', 'might', 'will' or 'will be taken', 'occur', or 'be achieved'. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts, but instead represent management's expectations, estimates, and projections regarding future events. Forward-looking statements involve risks and uncertainties, including, but not limited to, the factors described in greater detail in the 'Risks and Uncertainties' section of our management's discussion and analysis of financial condition and results of operations for the year ended September 30, 2024, which is available on the Company's profile at any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company assumes no obligation to update or alter any forward-looking statements, whether as a result of new information, further events, or otherwise, except as required by law.
Yahoo
12-03-2025
- Business
- Yahoo
Covalon To Hold Annual Meeting of Shareholders on Wednesday, March 19, 2025
MISSISSAUGA, Ontario, March 12, 2025--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, has announced that the annual meeting of shareholders of the Company will be held on Wednesday, March 19, 2025 at 2:00pm Eastern Time in a virtual-only format where shareholders may attend and participate in the meeting via live webcast. The meeting will include a presentation from Covalon's recently appointed CEO, Brent Ashton, with a Question and Answer session to follow. Registered shareholders and duly appointed proxyholders will be able to attend, participate, and vote at the Meeting online at Meeting ID being 1738, using Password "covalon2025" (case sensitive). If you are a registered shareholder and you want to appoint someone else (other than the Management nominees) to vote online at the Meeting, you must first submit your proxy indicating who you are appointing. You or your appointee must then register with TSX Trust in advance of the Meeting by emailing tsxtrustproxyvoting@ the "Request for Control Number" form, which can be found here: If you are a non-registered shareholder (shareholder who holds their shares through a broker, investment dealer, bank, trust company, custodian, nominee, or other intermediary) and want to vote online at the Meeting, you must appoint yourself as proxyholder and register with TSX Trust Company in advance of the Meeting by emailing tsxtrustproxyvoting@ the "Request for Control Number" form, which can be found here Registering your proxyholder is an additional step to be completed AFTER you have submitted your form of proxy or voting instruction form. Non-registered shareholders who have not duly appointed themselves as proxyholder will not be able to vote at the Meeting but will be able to attend the Meeting as guests. Guests are invited to attend the meeting by navigating to Meeting ID being 1738, and clicking on "I am a Guest". Copies of Covalon's Management Information Circular, financial statements, and MD&A can be obtained on SEDAR+ at and under Sedar Filings on the Investors tab of Covalon's website. Those interested in learning more about Covalon can visit or follow Covalon on LinkedIn, Facebook, Instagram, or X. About CovalonCovalon is a leading medical device company dedicated to improving patient outcomes through innovative and compassionate medical products and technologies. Our expertise spans advanced wound care, vascular access, and surgical consumables, with a strong focus on enhancing healing, reducing healthcare-associated infections (HAIs), and protecting skin integrity. Our solutions are designed for patients and made for care providers. The Company is listed on the TSX Venture Exchange (COV) and trades on the OTCQX Market (CVALF). To learn more about Covalon, visit our website at Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan", "estimate", "expect", "intend", or variations of such words and phrases or state that certain actions, events, or results "may", "could", "would", "might", "will" or "will be taken", "occur", or "be achieved". In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts, but instead represent management's expectations, estimates, and projections regarding future events. Forward-looking statements involve risks and uncertainties, including, but not limited to, the factors described in greater detail in the "Risks and Uncertainties" section of our management's discussion and analysis of financial condition and results of operations for the year ended September 30, 2024, which is available on the Company's profile at any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company assumes no obligation to update or alter any forward-looking statements, whether as a result of new information, further events, or otherwise, except as required by law. View source version on Contacts To learn more about Covalon, please contact: Investor Relations, Covalon Technologies investors@ Website: Sign in to access your portfolio
